In this technical session, Creative Biolabs has invited Dr. Leyton to describe the need to develop a more precise method in investigating nuclear transport dynamics of NLS-therapeutics. Moreover, Dr. Leyton will also present a de novo approach for generating novel NLSs with an atypical zero net-charge and evaluating various strategies to determine the worth for integration into NLS-therapeutics development.
During this webinar, we will discuss the following key points:
• Why nuclear targeting improves drug efficacy
• How nuclear transport functions
• What are the significant challenges for pharmaceuticals targeting the nucleus
Unless otherwise specifically stated in relation to each and any of the events listed on this page, the MLSC does not host or sponsor these events. The MLSC has no oversight or responsibility for the venue, content or host-organization related to these events. The MLSC has no affiliation with the organizations listing events or with the events, and provides this content and information as a convenience to visitors to the MLSC website.